Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080262 · ClinicalTrials.gov registry record · Phase 2
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
A Phase 2 study of Breast Cancer and Metastases, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 20
- Study locations
NCT00080262: Completed Phase 2 study of Breast Cancer and Metastases, sponsored by R-Pharm.
NCT00080262 is a Phase 2 study of Breast Cancer and Metastases that has completed, run by R-Pharm. The registered enrollment target is 125 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080262, a Phase 2 study of Breast Cancer and Metastases, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
Conditions Studied
Interventions
- DRUG Ixabepilone
Study Locations (20)
Tennessee
- Local Institution - Chattanooga
- Local Institution - Jackson
- Local Institution - Knoxville
- Local Institution - Nashville
North Carolina
- Local Institution - Asheville
- Local Institution - Charlotte
Texas
- Local Institution - Houston
- Local Institution - San Antonio
Other
- Local Institution - Buenos Aires
- Local Institution - Santa Fe
California
- Local Institution - La Verne
Connecticut
- Local Institution - Meriden
Florida
- Local Institution - Jacksonville
Maryland
- Local Institution - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00080262 record still lists
NCT00080262 is an interventional study that assigns participants to a tested intervention. The registered 125 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ixabepilone is the first listed.
NCT00080262 names 20 study sites across 14 states, led by Tennessee, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT00080262 about?
NCT00080262 is a clinical study titled "Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)". The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
What is the current status of trial NCT00080262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2004-02. Estimated completion is 2006-12.
What conditions does trial NCT00080262 study?
This clinical trial studies the following conditions: Breast Cancer, Metastases.
What interventions are being tested in trial NCT00080262?
The interventions under investigation include: Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00080262?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00080262 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00080262's enrollment target sits among peer trials
125 499th of 1224 higher than 722 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02717039 · 125 participants
Pharmacogenomics of Heparin-Induced Thrombocytopenia
- NCT02763033 · 125 participants · Phase 2
Dietary Manipulation of the Microbiome-metabolomic Axis for Mitigating GVHD in Allo HCT Patients
- NCT02793999 · 125 participants
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
- NCT03003299 · 125 participants · NA
PARTNER 3 Trial - Aortic Valve-in-Valve
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia